利用Axion Maestro检测药物心脏毒副作用-CiPA

Axion MaestroCiPA

CiPA Phase II

Axion MaestroMEA

*93%

*85%45%

*6.4%20%

12CiPA Phase II result.

 Axion Maestro 105Daniel Millard et. al.,Toxicological Sciences, 2018, 114;  Blinova et al., 2018, Cell Reports 24, 35823592

CiPA Phase I & II

CiPAMEA, microelectrical arrayhSCCMsFPD(Field potential duration)BPBeat periodAMP (Spike Amplitude)  (Arrhythmia Occurrence)

CiPAIIIICDIiCellAxiogenesisCor.4U18使3MEA8 (Millard et al., 2018)CiPA III10使522834Blinova et al., 2018CiPA IAxion BiosystemsII1051Axion

Axion Maestro

3. CiPA II28Ksenia Blinova, FDA, CiPA Phase II: Validation Study Results.

4. CiPA IIKsenia Blinova, FDA, CiPA Phase II: Validation Study Results.

Axion Maestro

MEAQT,MEAsFPDQT(5

MEAhSCCMsQT5

5. MEAQTClements, M. et al., Axion Biosystems.

LEAP and Contractility

Axion2018LEAPLocal extracellular action potentialEADEarly AfterPolarization.6

6. LEAPCMSotalol (hERG)Cor4U CMsEADsEAD)(Ranolazine)(Verapamil)TdP3Clements, M. et al., Axion Biosystems.

20194Contractility(78)

 

7contractility

8Contractility

FDACiPA (hPSCCMs)https://mp.weixin.qq.com/s/AZe_igtr471sJb1arRoJg


CiPA

42%FDA2003hERGhERGhERG

1使Verapamil3

22003

FDA2013CiPAICH S7BQT

CiPA

CiPA

1.in silicoIn silico广FDA

2.(hPSCCMs)in silico

3.CiPAQTECG Biomarker,J to TPQT

9CiPA CiPAhttp://cipaproject.org/aboutcipa/

In silicoCiPAFDA使ICH S7BICH E14使使

THE COMPLETE CARDIAC ASSAY: